Adverse effects of ethyl esters or oxidation products in omega-3 preparations?

Cardiovascular Journal of Africa

Volumn 25, Issue 2, 2014, Pages 86-87

  Rupp, Heinz ^a   Rupp, Karin G ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; DOCOSAHEXAENOIC ACID; ETHYLESTER; FISH OIL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AUTOOXIDATION; DIET SUPPLEMENTATION; DISEASE COURSE; HEALTH HAZARD; HEART FAILURE; HUMAN; LETTER; OXIDATION; PATIENT SAFETY; ANALYSIS;

DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS;

EID: 84900992884     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Opperman M, Benade S. Analysis of the omega-3 fatty acid content of South African fish oil supplements: a follow-up study. Cardiovasc J Afr 2013; 24: 297-302.
2. Rupp H, Rupp TP, Alter P, Maisch B. N-3 polyunsaturated fatty acids and statins in heart failure. Lancet 2009; 373: 378-379.
3. Rupp H, Rupp TP, Alter P, Maisch B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart 2010; 96: 595-598.
4. Rupp H, Rupp TP, Alter P, Maisch B. Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency". Can J Physiol Pharmacol 2012; 90: 55-73.
5. Bourdon JA, Bazinet TM, Arnason TT, Kimpe LE, Blais JM, While PA. Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of omega-3 polyunsaturated fatty acid supplements: implications for daily intake of dioxins and PCBs. Food Chem Toxicol 2010; 48: 3093-3097.
6. Gissi-Hf investigators. Effect of n-3 polyunsaturated fatty acids in patients wilh chronic heart failure (die GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
7. GISSI-Prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455.
8. Luley C, Wieland H, Grünwald J. Bioavailability of omega-3 fatty acids: ethylester preparations are as suitable as triglyceride preparations. Akt Ernähr Med 1990; 15: 123-125.
9. Rupp TP, Rupp KG, Alter P, Rupp H. Replacement of reduced highly unsaturated fatty acids (HUFA deficiency) in dilative heart failure: dosage of EPA/DHA and variability of adverse peroxides and aldehydes in dietary supplement fish oils. Cardiology 2013; 125: 223-231.
10. Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, Micol V. Roche E, Garcia-Garcia E. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int J Food Sci Nutr 2013; 64: 993-1000.
11. Ruyter B, Grimmer S, Thorkildsen T, Todorcevic M, Lalic M. Lite Oksiderte Omega-3 Oljer og Potensielle Helsefordeler. Trondheim: Rubin, 2010; 196: 1-60.